Ole Köhler-Forsberg1, Louisa G Sylvia2, Valerie L Ruberto2, Maya Kuperberg2, Alec P Shannon2, Vicki Fung3, Lindsay Overhage4, Joseph R Calabrese5, Michael Thase6, Charles L Bowden7, Richard C Shelton8, Melvin McInnis9, Thilo Deckersbach2, Mauricio Tohen10, James H Kocsis11, Terence A Ketter12, Edward S Friedman13, Dan V Iosifescu14, Susan McElroy15, Michael J Ostacher14, Andrew A Nierenberg2. 1. Psychosis Research Unit, Aarhus University Hospital Psychiatry, Denmark; Department of Clinical Medicin, Aarhus University, Aarhus, Denmark; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: karkoe@rm.dk. 2. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. 3. Mongan Institute, Massachusetts General Hospital; Department of Medicine, Harvard Medical School. 4. Mongan Institute, Massachusetts General Hospital. 5. Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA. 6. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA. 7. Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA. 8. Department of Psychiatry, University of Alabama at Birmingham, Birmingham, AL, USA. 9. Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA. 10. Department of Psychiatry, University of New Mexico Health Science Center, Albuquerque, NM, USA. 11. Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA. 12. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA. 13. Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 14. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. 15. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH and Lindner Center of HOPE, Mason, OH, USA.
Abstract
BACKGROUND: Bipolar disorder is a heritable disorder, and we aimed to assess the impact of family history of mental disorders in first-degree relatives on the severity and course of bipolar disorder. METHODS: The Bipolar CHOICE (lithium versus quetiapine) and LiTMUS (optimized treatment with versus without lithium) comparative effectiveness studies were similar trials among bipolar disorder outpatients studying four different randomized treatment arms for 24 weeks. Patients self-reported on six severe mental disorders among first-degree relatives. We performed ANOVA and linear regression regarding disease severity measures, sociodemographic and cardiometabolic markers and mixed effects linear regression to evaluate treatment response. RESULTS: Among 757 patients, 644 (85.1%) reported at least one first-degree relative with a severe mental disorder (mean=2.8; standard deviation=2.2; range=0-13). Depression (67.1%), alcohol abuse (51.0%) and bipolar disorder (47.0%) were the most frequently reported disorders. Familial psychiatric history correlated with several disease severity measures (hospitalizations, suicide attempts, and earlier onset) and sociodemographic markers (lower education and household income) but not with cardiometabolic markers (e.g. cholesterol or waist circumference) or cardiovascular risk scores, e.g. the Framingham risk score. Patients with familial psychiatric history tended to require more psychopharmacological treatment (p=0.054) but responded similarly (all p>0.1) to all four treatment arms. CONCLUSIONS: Our findings indicate that familial psychiatric history is common among outpatients with bipolar disorder and correlates with disease severity and sociodemographic measures. Patients with a greater familial psychiatric load required more intense treatment but achieved similar treatment responses compared to patients without familial psychiatric history.
BACKGROUND:Bipolar disorder is a heritable disorder, and we aimed to assess the impact of family history of mental disorders in first-degree relatives on the severity and course of bipolar disorder. METHODS: The Bipolar CHOICE (lithium versus quetiapine) and LiTMUS (optimized treatment with versus without lithium) comparative effectiveness studies were similar trials among bipolar disorder outpatients studying four different randomized treatment arms for 24 weeks. Patients self-reported on six severe mental disorders among first-degree relatives. We performed ANOVA and linear regression regarding disease severity measures, sociodemographic and cardiometabolic markers and mixed effects linear regression to evaluate treatment response. RESULTS: Among 757 patients, 644 (85.1%) reported at least one first-degree relative with a severe mental disorder (mean=2.8; standard deviation=2.2; range=0-13). Depression (67.1%), alcohol abuse (51.0%) and bipolar disorder (47.0%) were the most frequently reported disorders. Familial psychiatric history correlated with several disease severity measures (hospitalizations, suicide attempts, and earlier onset) and sociodemographic markers (lower education and household income) but not with cardiometabolic markers (e.g. cholesterol or waist circumference) or cardiovascular risk scores, e.g. the Framingham risk score. Patients with familial psychiatric history tended to require more psychopharmacological treatment (p=0.054) but responded similarly (all p>0.1) to all four treatment arms. CONCLUSIONS: Our findings indicate that familial psychiatric history is common among outpatients with bipolar disorder and correlates with disease severity and sociodemographic measures. Patients with a greater familial psychiatric load required more intense treatment but achieved similar treatment responses compared to patients without familial psychiatric history.
Authors: Rasim S Diler; John A Merranko; Danella Hafeman; Tina R Goldstein; Benjamin I Goldstein; Heather Hower; Mary Kay Gill; David A Axelson; Neal Ryan; Michael Strober; Martin B Keller; Shirley Yen; Jeffrey I Hunt; Lauren M Weinstock; Satish Iyengar; Boris B Birmaher Journal: J Affect Disord Date: 2022-01-13 Impact factor: 4.839
Authors: Camila N C Lima; Robert Suchting; Giselli Scaini; Valeria A Cuellar; Alexandra Del Favero-Campbell; Consuelo Walss-Bass; Jair C Soares; Joao Quevedo; Gabriel R Fries Journal: Eur Neuropsychopharmacol Date: 2022-07-08 Impact factor: 5.415
Authors: Afra van der Markt; Ursula M H Klumpers; Annemiek Dols; Marco P Boks; Annabel Vreeker; Aartjan T F Beekman; Ralph W Kupka Journal: Bipolar Disord Date: 2021-11-27 Impact factor: 5.345